This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s […]

The Nasonex Drug Ad analysis at DrugChatter.com is pretty close to even, with 40/60 split between people not liking and

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
The evolving concept of value add in university commercialisation
Go to paperABSTRACT: Universities have been challenged to assess what value creation mean…

I have just launched DrugChatter.com. DrugChatter mines the social internet  and taps into the DrugPatentWatch database to bring you public opinions

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Strategies for improving communication between scientists and the public
Go to paperABSTRACT: It is believed that a scientifically literate society benefit…

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Singapore’s biomedical science sector development strategy: Is it sustainable?
Go to paperABSTRACT: This paper outlines the strategic efforts undertaken by…

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?

BiologicPatentWatch concentrates deep knowledge on biologic drugs from more than 60 biotechnology companies, including more than 2,800 active and expired US patents and 41,000 patents spanning 91 international patent offices.

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Marketspace: Leading biotechnology players, 2002–08: Key products, indications and technologies

Go to paper

ABSTRACT: For the full year 2002, the top ten biotechnology houses generated combined revenues (= royalties/licensing income + ethical or product sales; product sales includes both diagnostic and prescription drugs) of US$15.9bn, a 27 per cent increase over 2001. Using Datamonitor’s proprietary forecasting methodology, the ethical sales of the ten leading biotechnology companies (Amgen, Genentech, Serono, Genzyme, Biogen, Chiron, MedImmune, Gilead, IDEC and Celltech) are forecast to grow from US$17…

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

• Management
• Policy
• Finance
• Law
• Regulation
• Bioethics

For more information, see the Journal of Commercial Biotechnology website